Newborn screening is an important public health service of screening infants soon after birth for potentially treatable conditions but not medically evident at the newborn age. Screening can be done through the primary care physician, pediatrician, or family doctor. Newborn screening can also be performed by the infant s nursery. Newborn screening tests scr
Global CAR-T Cell Therapy Market 57
Global CAR-T cell therapy market is set to witness a healthy CAGR of 46.35% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Rising cases of cancer and rising demand for effective method to cure cancer are factor for the growth of this market.
Competitive Analysis:
Global CAR-T cell therapy market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of CAR-T cell therapy market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Home / Top News / Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial
Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021
Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy
WORCESTER, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today provided updates on MB-107 and MB-207, its lentiviral gene therapies for the treatment of X-linked severe combined immunodeficien
5
Head and Neck Cancer Drug Market Research Report conducts a deep estimation of the present state of the Head and Neck Cancer Drug Industry with the definition, classification, and market scope. The data included in the report has been generated by consulting industry leaders and taking inputs from them. The topmost subdivisions of the market have been emphasized and these divisions have been presented by giving statistics on their current state by the end of the forecast horizon.
Head and Neck Cancer Drug Market Insight:
Global head and neck cancer drug market is rise gradually to an estimated value of USD 2.59 Billion by 2026 registering a CAGR of 8.1% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.
NEW YORK, NY / ACCESSWIRE / January 24, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress Biotech" or "the Company") (NASDAQ:FBIO) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Fortress Biotech securities between December 11, 2019 and October 9, 2020 both dates inclusive (the "Class Period").